Patents by Inventor Martin P. Maguire

Martin P. Maguire has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240115543
    Abstract: The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
    Type: Application
    Filed: December 8, 2023
    Publication date: April 11, 2024
    Inventors: Martin P. Maguire, Elise Rioux, Harry J. Leighton
  • Publication number: 20230414553
    Abstract: The present invention includes surprisingly water-soluble salts of a phenylalkylamine compound that are potent antagonists of L-type calcium channels. Aqueous solutions including salts of the instant invention are formulated for nasal administration and provide a novel therapeutic platform for the treatment of suable angina, migraine, and cardiac arrhythmia, such as paroxysmal supraventricular tachycardia.
    Type: Application
    Filed: September 6, 2023
    Publication date: December 28, 2023
    Inventor: Martin P. MAGUIRE
  • Publication number: 20230255923
    Abstract: The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
    Type: Application
    Filed: April 24, 2023
    Publication date: August 17, 2023
    Inventors: Martin P. MAGUIRE, Elise RIOUX, Harry J. LEIGHTON
  • Publication number: 20230157990
    Abstract: The present invention includes surprisingly water-soluble salts of a phenylalkylamide compound that are potent antagonists of L-type, calcium channels. Aqueous solutions including salts of the instant invention are formulated for nasal administration and provide a novel therapeutic platform for the treatment of stable angina, migraine, and cardiac arrhythmia, such as paroxysmal supraventricular tachycardia.
    Type: Application
    Filed: January 13, 2023
    Publication date: May 25, 2023
    Inventor: Martin P. MAGUIRE
  • Publication number: 20220296556
    Abstract: The present invention includes surprisingly water-soluble salts of a phenylalkylamine compound that are potent antagonists of L-type calcium channels. Aqueous solutions including salts of the instant invention are formulated for nasal administration and provide a novel therapeutic platform for the treatment of stable angina, migraine, and cardiac arrhythmia, such as paroxysmal supraventricular tachycardia.
    Type: Application
    Filed: June 2, 2022
    Publication date: September 22, 2022
    Inventor: Martin P. MAGUIRE
  • Publication number: 20220142963
    Abstract: The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
    Type: Application
    Filed: January 26, 2022
    Publication date: May 12, 2022
    Inventors: Martin P. MAGUIRE, Elise RIOUX, Harry J. LEIGHTON
  • Publication number: 20220040139
    Abstract: The present invention includes surprisingly water-soluble salts of a phenylalkylamine compound that are potent antagonists of L-type calcium channels. Aqueous solutions including salts of the instant invention are formulated for nasal administration and provide a novel therapeutic platform for the treatment of stable angina, migraine, and cardiac arrhythmia, such as paroxysmal supraventricular tachycardia.
    Type: Application
    Filed: October 26, 2021
    Publication date: February 10, 2022
    Inventor: Martin P. MAGUIRE
  • Publication number: 20210315855
    Abstract: The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
    Type: Application
    Filed: June 22, 2021
    Publication date: October 14, 2021
    Inventors: Martin P. MAGUIRE, Elise RIOUX, Harry J. LEIGHTON
  • Publication number: 20210205258
    Abstract: The present invention includes surprisingly water-soluble salts of a phenylalkylamine compound that are potent antagonists of L-type calcium channels. Aqueous solutions including salts of the instant invention are formulated for nasal administration and provide a novel therapeutic platform for the treatment of stable angina, migraine, and cardiac arrhythmia, such as paroxysmal supraventricular tachycardia.
    Type: Application
    Filed: March 18, 2021
    Publication date: July 8, 2021
    Inventor: Martin P. MAGUIRE
  • Publication number: 20210059972
    Abstract: The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
    Type: Application
    Filed: November 12, 2020
    Publication date: March 4, 2021
    Inventors: Martin P. MAGUIRE, Elise RIOUX, Harry J. LEIGHTON
  • Publication number: 20200368195
    Abstract: The present invention includes surprisingly water-soluble salts of a phenylalkylamine compound that are potent antagonists of L-type calcium channels. Aqueous solutions including salts of the instant invention are formulated for nasal administration and provide a novel therapeutic platform for the treatment of stable angina, migraine, and cardiac arrhythmia, such as paroxysmal supraventricular tachycardia.
    Type: Application
    Filed: August 13, 2020
    Publication date: November 26, 2020
    Inventor: Martin P. MAGUIRE
  • Publication number: 20200230097
    Abstract: The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
    Type: Application
    Filed: April 9, 2020
    Publication date: July 23, 2020
    Inventors: Martin P. MAGUIRE, Elise RIOUX, Harry J. LEIGHTON
  • Publication number: 20200121631
    Abstract: The present invention includes surprisingly water-soluble salts of a phenylalkylamine compound that are potent antagonists of L-type calcium channels. Aqueous solutions including salts of the instant invention are formulated for nasal administration and provide a novel therapeutic platform for the treatment of stable angina, migraine, and cardiac arrhythmia, such as paroxysmal supraventricular tachycardia.
    Type: Application
    Filed: December 19, 2019
    Publication date: April 23, 2020
    Inventor: Martin P. Maguire
  • Publication number: 20190380993
    Abstract: The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
    Type: Application
    Filed: August 29, 2019
    Publication date: December 19, 2019
    Inventors: Martin P. MAGUIRE, Elise RIOUX, Harry J. LEIGHTON
  • Publication number: 20190269643
    Abstract: The present invention includes surprisingly water-soluble salts of a phenylalkylamine compound that are potent antagonists of L-type calcium channels. Aqueous solutions including salts of the instant invention are formulated for nasal administration and provide a novel therapeutic platform for the treatment of stable angina, migraine, and cardiac arrhythmia, such as paroxysmal supraventricular tachycardia.
    Type: Application
    Filed: May 17, 2019
    Publication date: September 5, 2019
    Inventor: Martin P. MAGUIRE
  • Publication number: 20190142781
    Abstract: The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
    Type: Application
    Filed: January 14, 2019
    Publication date: May 16, 2019
    Inventors: Martin P. MAGUIRE, Elise RIOUX, Harry J. LEIGHTON
  • Publication number: 20190022048
    Abstract: The present invention includes surprisingly water-soluble salts of a phenylalkylamine compound that are potent antagonists of L-type calcium channels. Aqueous solutions including salts of the instant invention are formulated for nasal administration and provide a novel therapeutic platform for the treatment of stable angina, migraine, and cardiac arrhythmia, such as paroxysmal supraventricular tachycardia.
    Type: Application
    Filed: September 27, 2018
    Publication date: January 24, 2019
    Inventor: Martin P. MAGUIRE
  • Patent number: 10117848
    Abstract: The present invention includes surprisingly water-soluble salts of a phenylalkylamine compound that are potent antagonists of L-type calcium channels. Aqueous solutions including salts of the instant invention are formulated for nasal administration and provide a novel therapeutic platform for the treatment of stable angina, migraine, and cardiac arrhythmia, such as paroxysmal supraventricular tachycardia.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: November 6, 2018
    Assignee: Milestone Pharmaceuticals Inc.
    Inventor: Martin P. Maguire
  • Publication number: 20180280339
    Abstract: The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
    Type: Application
    Filed: June 4, 2018
    Publication date: October 4, 2018
    Inventors: Martin P. MAGUIRE, Elise RIOUX, Harry J. LEIGHTON
  • Patent number: 10010524
    Abstract: The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: July 3, 2018
    Assignee: Milestone Pharmaceuticals Inc.
    Inventors: Martin P. Maguire, Elise Rioux, Harry J. Leighton